CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...
Phase 2
Louisville, Kentucky, United States and 20 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Louisville, Kentucky, United States and 176 other locations
in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer...
Phase 3
Louisville, Kentucky, United States and 213 other locations
following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...
Phase 3
Louisville, Kentucky, United States and 237 other locations
preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected i...
Phase 1
Louisville, Kentucky, United States and 7 other locations
The primary objective of this study is to evaluate progression-free survival (PFS) by blinded independent central review (BICR) in patients treated w...
Phase 3
Louisville, Kentucky, United States and 116 other locations
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer...
Phase 1, Phase 2
Louisville, Kentucky, United States and 45 other locations
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced an...
Phase 2
Louisville, Kentucky, United States and 22 other locations
the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian...
Phase 1, Phase 2
Louisville, Kentucky, United States and 51 other locations
to find out if ZW171 is safe and can treat participants with advanced (locally advanced \[inoperable\] and/or metastatic) mesothelin-expressing cancers...
Phase 1
Louisville, Kentucky, United States
Clinical trials
Research sites
Resources
Legal